Compare Ascendis Pharma A/S (ASND) vs Mattel Inc (MAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Mattel Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Mattel Inc trades at $13.36 (market cap $3.87B). The key difference: Ascendis Pharma A/S is far larger — about 4.6× Mattel Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Mattel Inc nearer its low. Which is the better fit depends on your goals.
| ASND | MAT | |
|---|---|---|
Market Cap | $17.74B | $3.87B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $22.16 |
52-Week Low | $163.32 | $13.05 |
Enterprise Value | $18.11B | $5.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
MAT trades at $13.33, up 1.14% today, with a bearish technical signal from moving averages and oscillators showing neutral RSI levels. The company reported a net income of $397.58M in 2025, with a P/E of 8.54 and ROE of 23.56% indicating solid profitability. Recent news includes expansion of UNO Social Clubs and upcoming Q2 2026 earnings release on August 4, 2026.
The stock presents a mixed outlook: analyst consensus is a Buy with a $14.50 price target, but recent earnings misses and a negative net cash flow of -$145M in 2025 pose risks. Upside potential exists from brand expansions and Comic-Con product launches, while competitive pressures and debt levels of $2.33B require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
